Ethics committees and IRBs do not send materials back because they enjoy extra paperwork. They reject translations when the package fails to demonstrate that participants will genuinely understand what they are signing. A missing Accuracy Certificate, an unsigned attestation, or a seal that does not match local expectations can push a study back by weeks or months. In an industry where every day of delay carries measurable costs, that is never a minor administrative hiccup.
Tufts Center for the Study of Drug Development research has long quantified the damage. Average unrealized sales impact sits around $500,000 per day of delay, while direct operational costs for Phase II and III trials often run near $40,000 per day. A four-week setback driven by a rejected consent package can therefore exceed a million dollars in combined direct costs and lost opportunity, depending on phase and therapeutic area. Sponsors and CROs that treat translation as a last-minute procurement item absorb those costs repeatedly.
What “certified translation” actually means in this context
Regulators do not always use identical language. FDA regulations (21 CFR 50 and the Common Rule at 45 CFR 46) require that informed consent information be “understandable to the subject.” They do not explicitly demand a “certified translator” in every case. What they do demand is evidence that the translated materials accurately convey the approved English content and that qualified people prepared them. Most IRBs and Research Ethics Committees operationalize that expectation through a Certificate of Translation Accuracy (also called a Certificate of Accuracy or CoT).
A proper certificate typically states that the translator or agency is competent in both the source and target languages, that the translation is complete and accurate, and that it reflects the IRB-approved source document. It names the translator or agency, lists credentials or qualifications, identifies the specific document and version, and carries a signature and date. Some institutions accept an agency letterhead attestation. Others require notarization or a specific official stamp. Chapman University, Duke Health, the NCI CIRB, and many commercial IRBs publish explicit guidance requiring the certificate (or an equivalent verification form) whenever non-English materials are submitted.
For higher-risk or patient-facing documents—especially Informed Consent Forms—many committees also expect documented forward-and-back translation plus reconciliation. The back-translation is not always a legal mandate in itself; it is practical evidence that the “understandable” standard has been met. ICH E6(R3), now in force in the EU, further raises the bar by making the sponsor accountable for the entire translation process and requiring that proof sit in the Trial Master File: translator qualifications, version control, reconciliation notes, and sign-off.
Stamping and sealing practices vary by country and by receiving body. In some jurisdictions an agency certificate on letterhead is sufficient. In others, local notarial or official seals are expected. The common failure point is submitting a clean linguistic translation without the accompanying statement of accuracy and qualifications. Ethics committees are not checking literary elegance; they are checking whether the file will stand up later if an inspector or auditor asks how the sponsor ensured participants understood the risks.
Real-world delays that started with missing certification
These are not theoretical risks. In one multi-country review of precision-medicine trials, four of fourteen studies saw Brazilian ethics committees query risk language that had been rendered more definitive than the hedged English source. Full ICF revision, re-approval, and re-consent of hundreds of already-enrolled participants added roughly eleven weeks. In another set of cases, simplified response scales on translated Case Report Forms collapsed a five-point severity hierarchy into four points in certain languages. Database lock was delayed by six weeks while statisticians performed post-hoc mapping.
Mexican site experience shared in MRCT Center discussions is typical of start-up friction: waiting for properly prepared Spanish materials routinely added three to six weeks before ethics submission could even begin. Errors discovered later forced another correction-and-resubmission cycle. Across multiple reported experiences, cumulative translation-related delays easily reach a month or more per affected country. When those delays hit several countries simultaneously, the commercial impact compounds quickly.
The pattern is consistent. Sponsors who treat the Certificate of Accuracy as optional paperwork discover it is the practical gatekeeper. Committees rarely reject a translation solely because a particular word choice feels imperfect. They reject it when the package lacks the formal attestation that lets them close their own compliance file.
Building a package that survives first review
The most reliable approach is to treat certification as part of the deliverable, not an afterthought. Start with the English master approved by the IRB or ethics committee; only then translate. Use qualified medical translators with documented subject-matter experience. For patient-facing materials, build in independent review or formal back-translation with reconciliation notes. Deliver a Certificate of Accuracy that matches protocol version dates, study numbers, and document titles exactly. Keep translator CVs or qualification summaries available for the TMF. Align version control so that every language version can be traced to the same source.
ISO 17100-aligned processes help because they require a second qualified linguist to revise every translation and generate a clear audit trail. Many experienced sponsors now request the certificate template in advance and treat it as a standing checklist item rather than a scramble at submission time.
Ethics committees are not trying to slow research. They are protecting the fundamental requirement that consent be informed. When the documentation proves that requirement has been met, the package moves. When it does not, the clock stops.
Artlangs Translation has spent more than twenty years supporting life-sciences and clinical research teams across 230-plus languages. Its network of over 20,000 professional linguists includes specialists in clinical trial documentation, regulatory submissions, and patient-facing materials. Beyond certified clinical translation, the company handles video localization, short-drama subtitle localization, game localization, multilingual dubbing for short-form content and audiobooks, and multilingual data annotation and transcription. Teams that integrate proper certification and version-controlled processes from the outset routinely avoid the multi-week setbacks that still catch others by surprise.
